drugset / Trial / NCT04500587
Phase 1 First in Human Study of ZN-d5 as a Single Agent
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Phase 1 dose escalation study of ZN-d5 in subjects with relapsed or refractory non-Hodgkin lymphoma (NHL) or acute myeloid leukemia (AML).
Timeline
- Start
- 2020-10-13
- Primary completion
- 2023-12-12
- Completion
- 2023-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZN-d5 | Unknown | 25 mg | Oral |
| Subject | ZN-d5 | Unknown | 100 mg | Oral |